Cover Image
市場調查報告書

癌症疫苗的全球市場:2015年∼2019年

Global Cancer Vaccines Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 333142
出版日期 內容資訊 英文 64 Pages
訂單完成後即時交付
價格
Back to Top
癌症疫苗的全球市場:2015年∼2019年 Global Cancer Vaccines Market 2015-2019
出版日期: 2015年06月17日 內容資訊: 英文 64 Pages
簡介

全球癌症疫苗市場,預計2014年∼2019年以27.24%的年複合成長率成長。

本報告提供全球癌症疫苗市場相關調查分析、市場規模與成長率、市場趨勢、市場的推動要素與課題、市場機會驗證、主要供應商等相關的系統性資訊。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 疫苗的認證流程

第7章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 市場區隔:各疫苗臨床應用

  • 預防疫苗
  • 治療疫苗

第9章 全球預防疫苗市場

  • 市場概要
  • 市場規模與預測

第10章 全球治療疫苗市場

  • 市場概要
  • 市場規模與預測

第11章 地理區分

第12章 購買標準

第13章 領導品牌分析

  • Gardasil和Cervarix比較研究

第14章 開發平台的組合

第15章 推動市場成長要素

第16章 成長推動因素與其影響

第17章 市場課題

第18章 成長推動因素與課題的影響

第19章 市場趨勢

第20章 趨勢與其影響

第21章 業者情勢

  • 競爭模式
  • 市場佔有率分析
  • 其他、未來的有力供應商

第22章 癌症疫苗供應商的機會

第23章 主要供應商分析

  • Dendreon
  • GlaxoSmithKline
  • Merck & Co. Inc.

第24章 相關報告

圖表

目錄
Product Code: IRTNTR6198

About Cancer Vaccines

Cancer vaccines are biological preparations that stimulate or strengthen a person's immune system against cancer. Cancer vaccines are usually administered intravenously. They can be used in both adults and children. The vaccines can be broadly classified into two: prophylactic and therapeutic vaccines. Prophylactic vaccines are used for the prevention of cancer, whereas therapeutic vaccines are used for treatment of cancer.

Technavio's analysts forecast the global cancer vaccines market to grow at a CAGR of 27.24% over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the global cancer vaccines market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various therapeutic and prophylactic cancer vaccines.

This report covers the present scenario and the growth prospects of the global cancer vaccines market for the period 2015-2019 in the following three regions:

  • Americas: The principal countries focused upon in this region are the US, Canada, Mexico, and Brazil
  • EMEA: The principal countries focused upon in this region are the UK; Germany; Italy; France; Spain and Middle Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and UAE
  • APAC: The principal countries focused upon in this region are Japan, China, Australia, Singapore, South Korea, and India. APAC is one of the major markets that is untapped by the leading vendors

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

Technavio's report, Global Cancer Vaccines Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC; it also covers the global cancer vaccines market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Dendreon
  • GlaxoSmithKline
  • Merck

Other Prominent Vendors

  • Aduro BioTech
  • Advantagene
  • Advaxis
  • Agenus
  • AlphaVax
  • Altor BioScience
  • Amgen
  • Antigen Express
  • Argos Therapeutics
  • AVAX Technologies
  • Bavarian Nordic
  • Biothera
  • Bristol-Myers Squibb
  • Celldex Therapeutics
  • Cel-Sci
  • CureVac
  • Cytos
  • Galena Biopharma
  • Genexine
  • GlobeImmune
  • Gradalis
  • Heat Biologics
  • Immatics
  • ImmunoCellular Therapeutics
  • Immutep
  • Inovio Pharmaceuticals
  • Isa Pharmaceuticals
  • Juvaris Biotherapeutics
  • MedImmune
  • NewLink Genetics
  • Northwest Biotherapeutics
  • NovaRx
  • OncoThyreon
  • Oncovir
  • Oxford BioMedica
  • Prima BioMed
  • Progenics
  • Provectus Biopharmaceuticals
  • Sanofi
  • Sotio
  • Transgene
  • Ubivac
  • Vaccinogen
  • Vaxon Biotech
  • Vical

Market Driver

  • Increased Prevalence of Cancers
  • For a full, detailed list, view our report

Market Challenge

  • Cold Chain Management
  • For a full, detailed list, view our report

Market Trend

  • Strategic Alliances
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Vaccine Approval Process

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Five Forces Analysis

08. Market Segmentation by Clinical Application of Vaccines

  • 08.1. Prophylactic Vaccines
  • 08.2. Therapeutic Vaccines

09. Global Prophylactic Vaccines Market

    • 09.1.1. Market Overview
    • 09.1.2. Market Size and Forecast

10. Global Therapeutic Vaccines Market

    • 10.1.1. Market Overview
    • 10.1.2. Market Size and Forecast

11. Geographical Segmentation

12. Buying Criteria

13. Key Brand Analysis

  • 13.1. Comparative Study between Gardasil and Cervarix

14. Pipeline Portfolio

    • 14.1.1. Prostvac
    • 14.1.2. Neuvax
    • 14.1.3. Rindopepimut
    • 14.1.4. MVax
    • 14.1.5. DCVax-L
    • 14.1.6. ProstAtak
    • 14.1.7. Talimogene Laherparepvec
    • 14.1.8. IMA901
    • 14.1.9. Imprime PGG
    • 14.1.10. OncoVAX
    • 14.1.11. Lucanix
    • 14.1.12. DCVAC/PCa

15. Market Growth Drivers

16. Drivers and their Impact

17. Market Challenges

18. Impact of Drivers and Challenges

19. Market Trends

20. Trends and their Impact

21. Vendor Landscape

  • 21.1. Competitive Scenario
    • 21.1.1. Key News
    • 21.1.2. Mergers and Acquisitions
  • 21.2. Market Share Analysis 2014
    • 21.2.1. Merck
    • 21.2.2. Dendreon
    • 21.2.3. GlaxoSmithKline
  • 21.3. Other and Future Prominent Vendors

22. Opportunities for Cancer Vaccine Vendors

23. Key Vendor Analysis

  • 23.1. Dendreon
    • 23.1.1. Key Facts
    • 23.1.2. Business Overview
    • 23.1.3. Recent Developments
    • 23.1.4. SWOT Analysis
  • 23.2. GlaxoSmithKline
    • 23.2.1. Key facts
    • 23.2.2. Business overview
    • 23.2.3. Business segmentation by revenue 2014
    • 23.2.4. Business segmentation by revenue 2013 and 2014
    • 23.2.5. Geographical segmentation by revenue 2014
    • 23.2.6. Business strategy
    • 23.2.7. Recent developments
    • 23.2.8. SWOT analysis
  • 23.3. Merck & Co. Inc.
    • 23.3.1. Key Facts
    • 23.3.2. Business Overview
    • 23.3.3. Business Segmentation by Revenue 2013
    • 23.3.4. Business Segmentation by Revenue 2012 and 2013
    • 23.3.5. Sales by Geography
    • 23.3.6. Business Strategy
    • 23.3.7. Key Developments
    • 23.3.8. SWOT Analysis

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Vaccine Approval Process
  • Exhibit 3: Global Cancer Vaccines Market 2014-2019 ($ millions)
  • Exhibit 4: Segmentation of Global Cancer Vaccines Market by Clinical Application of Vaccines
  • Exhibit 5: Segmentation of Global Cancer Vaccines Market by Clinical Application of Vaccines, 2014
  • Exhibit 6: Global Prophylactic Vaccines Market 2014-2019 ($ millions)
  • Exhibit 7: Global Therapeutic Vaccines Market 2014-2019 ($ millions)
  • Exhibit 8: Segmentation of the Global Cancer Vaccines Market by Geography, 2014
  • Exhibit 9: Global Cancer Vaccines Market: Comparison of the Major Brands
  • Exhibit 10: Gardasil and Cervarix: A Comparative Study
  • Exhibit 11: Key Late-stage Vaccines Under Development
  • Exhibit 12: Drivers of the Global Cancer Vaccines Market
  • Exhibit 13: Challenges of the Global Cancer Vaccines Market
  • Exhibit 14: Trends of the Global Cancer Vaccines Market
  • Exhibit 15: Global Revenue and YoY Growth Rate of Gardasil 2010-2014
  • Exhibit 16: Global Revenue and YoY Growth Rate of Provenge 2011-2014
  • Exhibit 17: Global Revenue and YoY Growth Rate of Cervarix 2010-2014
  • Exhibit 18: Opportunity Analysis: Global Cancer Vaccine Market
  • Exhibit 19: GlaxoSmithKline: Business segmentation by revenue 2014
  • Exhibit 20: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billion)
  • Exhibit 21: GlaxoSmithKline: Geographical segmentation by revenue 2014
  • Exhibit 22: Merck & Co. Inc.: Business Segmentation by Revenue 2013
  • Exhibit 23: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 24: Merck & Co. Inc.: Sales by Geography 2013
Back to Top